| Gloria F Cantor, APRN CNS | |
|
7066 Stillwater Blvd N, Oakdale, MN 55128-3937 | |
| (651) 777-5222 | |
| (651) 251-5111 |
| Full Name | Gloria F Cantor |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist |
| Location | 7066 Stillwater Blvd N, Oakdale, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114990066 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364S00000X | Clinical Nurse Specialist | 0994103 (Minnesota) | Primary |
| Entity Name | Canvas Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922051325 PECOS PAC ID: 8729073978 Enrollment ID: O20040416001178 |
News Archive
A new nonsteroidal, anti-inflammatory therapy made from a human protein significantly decreases disease signs of asthma in mice, opening the possibility of a new asthma therapy for patients who do not respond to current steroid treatments. Results of this therapy in an animal model were presented at The Endocrine Society's 92nd Annual Meeting in San Diego.
In their efforts to understand the complex biology of life, scientists often seek to isolate individual elements of the puzzle for study, to break the problem down to a more manageable size. Single genes and molecules are closely analyzed to better understand their specific interactions with other single entities within larger systems.
Allos Therapeutics, Inc. today announced that results from the Phase 2b investigational trial of FOLOTYN (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) will be presented at the 35th European Society of Medical Oncology (ESMO) Congress
BioScrip, Inc. today announced 2015 second quarter financial results. Second quarter revenue from continuing operations was $262.4 million and the net loss from continuing operations was $243.2 million, or $3.60 loss per diluted share, which includes a $238.0 million pre-tax goodwill impairment charge resulting from a decline in the Company's common stock price and related market capitalization, as well as an $8.6 million incremental pre-tax bad debt charge predominately attributable to aged accounts receivable balances over 365 days old.
A new study from the Swedish medical university Karolinska Institutet presents a new technique that makes drug testing possible through exhaled air for the first time. By examining people who had received emergency care for an amphetamine overdose, the researchers found that in all cases there were traces of amphetamine and metamphetamine in the exhaled breath.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gloria F Cantor, APRN CNS 7066 Stillwater Blvd N, Oakdale, MN 55128-3937 Ph: (651) 777-5222 | Gloria F Cantor, APRN CNS 7066 Stillwater Blvd N, Oakdale, MN 55128-3937 Ph: (651) 777-5222 |
News Archive
A new nonsteroidal, anti-inflammatory therapy made from a human protein significantly decreases disease signs of asthma in mice, opening the possibility of a new asthma therapy for patients who do not respond to current steroid treatments. Results of this therapy in an animal model were presented at The Endocrine Society's 92nd Annual Meeting in San Diego.
In their efforts to understand the complex biology of life, scientists often seek to isolate individual elements of the puzzle for study, to break the problem down to a more manageable size. Single genes and molecules are closely analyzed to better understand their specific interactions with other single entities within larger systems.
Allos Therapeutics, Inc. today announced that results from the Phase 2b investigational trial of FOLOTYN (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) will be presented at the 35th European Society of Medical Oncology (ESMO) Congress
BioScrip, Inc. today announced 2015 second quarter financial results. Second quarter revenue from continuing operations was $262.4 million and the net loss from continuing operations was $243.2 million, or $3.60 loss per diluted share, which includes a $238.0 million pre-tax goodwill impairment charge resulting from a decline in the Company's common stock price and related market capitalization, as well as an $8.6 million incremental pre-tax bad debt charge predominately attributable to aged accounts receivable balances over 365 days old.
A new study from the Swedish medical university Karolinska Institutet presents a new technique that makes drug testing possible through exhaled air for the first time. By examining people who had received emergency care for an amphetamine overdose, the researchers found that in all cases there were traces of amphetamine and metamphetamine in the exhaled breath.
› Verified 8 days ago